ccr logo

Critical Care Reviews Newsletter

February 24th 2013

Welcome

Hello

Welcome to the 64th Critical Care Reviews Newsletter, bringing you the best critical care research published in the past week, plus a wide range of free full text review articles and guidelines from over 300 clinical and scientific journals.

This week's research studies include yet more evidence that hydroxyethyl starches are harmful, two studies on the new oral anticoagulants, two studies on coronary revascularization and a phase two study investigating a novel anti-sepsis therapy. There are several editorials and commentaries, including a debate on a potential move to a seven day working week. Amongst the 56 review articles highlighted are three papers on a novel topic, psychiatric emergencies, which could present to the intensivist.

The topic for This Week's Papers is complications of transfusion, starting with a paper on transfusion-related acute lung injury in tomorrow's Paper of the Day.

 

Research

Journal of the American Medical Association:     Hydroxyethyl Starch

To evaluate the association of hydroxyethyl starch use with mortality and acute kidney injury, Zarychanski and colleagues performed a systematic review and meta analysis (initially 38 trials with 10,880 patients, refined to 31 trials with 10,290 after the exclusion of retracted trials) comparing hydroxyethyl starch to crystalloids, albumin, or gelatin. The majority of trials were categorized as having an unclear risk or high risk of bias. Excluding the retracted studies, hydroxyethyl starch was associated with increased mortality (relative risk 1.09; 95% CI 1.02 to 1.17; I2 0%; absolute risk 1.51%; 95% CI 0.02% to 3.00%), increased renal failure among 8725 patients (RR 1.27; 95% CI 1.09 to 1.47; I2 26%; AR 5.45%; 95% CI 0.44% to 10.47%), and increased use of renal replacement therapy among 9258 patients (RR 1.32; 95% CI 1.15 to 1.50; I2 0%; AR 3.12%; 95% CI 0.47% to 5.78%). Conclusion: In a systematic review and meta analysis, hydroxyethyl starch administration was associated with increased risks of death, renal failure and renal replacement therapy.

Abstract: Zarychanski. Association of Hydroxyethyl Starch Administration With Mortality and Acute Kidney Injury in Critically Ill Patients Requiring Volume Resuscitation: A Systematic Review and Meta-analysis. JAMA 2013;309(7):678

 

New England Journal of Medicine:     Dabigatran

In two double-blind, randomized trials, dabigatran (150 mg twice daily) was compared with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. In the active-control study, for rates of recurrent venous thromboembolism, dabigatran (1.8%; 26/1430) was not inferior to warfarin (1.3%; 18/1426) (hazard ratio with dabigatran, 1.44; 95% CI 0.78-2.64; P=0.01 for noninferiority). Similarly, there was no difference in major bleeding; dabigatran group (0.9%, 13/1430) versus warfarin group (1.8%; 25/1426) (hazard ratio 0.52; 95% CI 0.27-1.02), although major or clinically relevant bleeding was less frequent with dabigatran (HR 0.54; 95% CI 0.41-0.71). Acute coronary syndromes were more common in the dabigatran group (0.9%; 13/1430) versus (0.2%; 3/1426) (P=0.02). In the placebo-control study, recurrent venous thromboembolism was less common in the dabigatran group (0.4%; 3/681) than in the placebo group (5.6%; 37/662) (HR 0.08; 95% CI 0.02-0.25; P<0.001). Major or clinically relevant bleeding occurred more frequently in the dabigatran group (5.3%; 36/681) versus (1.8%; 12/662) (HR 2.92; 95% CI 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. Conclusion:  Dabigatran was not inferior to warfarin for the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo.

Abstract:  Schulman. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism (RE-MEDY and the RE-SONATE Trials). N Engl J Med 2013;368:709-718

 

New England Journal of Medicine:     Apixiban

Agnelli et al completed a randomized, double-blind study, comparing two doses of apixaban (2.5 mg and 5 mg, twice daily for 12 months) with placebo in 2486 patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 8.8% (73/829) in those receiving placebo, 1.7% (14/840) in those receiving apixaban 2.5 mg (a difference of 7.2%; 95% CI 5.0 to 9.3) and 1.7% (14/813) in those receiving 5 mg of apixaban (a difference of 7.0%; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. Conclusions:  Extended anticoagulation with apixaban, at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg), reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding.

Abstract:  Agnelli. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med 2013;368:699-708

 

The Lancet:     Coronary Revascularization

Mohr et al report the 5-year results of the multi-centre, randomized SYNTAX trial, which compared coronary artery bypass graft surgery (CABG) with percutaneous coronary intervention (PCI) for the treatment of patients with left main coronary disease or three-vessel disease. 1800 patients were randomly assigned to CABG (n=897) or PCI (n=903). Kaplan-Meier estimates of the major endpoint, a composite rate of major adverse cardiac and cerebrovascular events, were higher in the PCI group (37.3 versus 26·9%, p<0·0001). Likewise, estimates of myocardial infarction ( 9·7% versus 3·8%; p<0·0001) and repeat revascularisation (25·9% versus 13·7% vs ; p<0·0001) were significantly increased with PCI versus CABG. Neither all-cause death (PCI group 13·9% versus CABG group 11·4%; p=0·10) nor stroke (PCI group 2.4% versus CABG group 3·7%; p=0·09) were  significantly different. In patients with intermediate or high SYNTAX scores, major adverse cardiac and cerebrovascular events was significantly increased with PCI (intermediate score, PCI group 36·0% versus CABG group 25·8%, p=0·008; high score, PCI group 44·0% versus CABG group 26·8%; p<0·0001). Conclusion: CABG is superior to PCI for complex lesions (high or intermediate SYNTAX scores), although for less complex disease (low SYNTAX scores) or left main coronary disease (low or intermediate SYNTAX scores), PCI is an acceptable alternative.

Abstract:  Mohr. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381(9867):629-638

 

Critical Care Medicine:     Sepsis

Guntupalli et al completed a prospective, randomized, double-blind, placebo-controlled, multicenter phase 2 trial, investigating whether enteral lactoferrin (talactoferrin), a glycoprotein with anti-infective and anti-inflammatory properties which contributes to gastrointestinal mucosal barrier integrity, could reduce 28-day all-cause mortality in 194 patients with severe sepsis. The all-cause mortality at 28 days was 26.9% in the placebo group and 14.4% in the talactoferrin group (two-sided p = 0.052), representing a 12.5% absolute and a 46.5% relative reduction in mortality, meeting the protocol-specified primary endpoint. Reduction in all cause mortality was sustained at 6 months (p = 0.039). These reductions in mortality were observed across a wide spectrum of subgroups. The drug was well tolerated with a safety profile similar to that of placebo. Conclusion: Enteral administration of talactoferrin reduced 28-day all-cause mortality in patients with severe sepsis.

Abstract:  Guntupalli. A Phase 2 Randomized, Double-Blind, Placebo–Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis. Critical Care Medicine 2013;41(3):706-716

 

JACC Cardiovascular Interventions:     PCI post Acute Myocardial Infarction with Cardiac Arrest

Mylotte et al conducted a multicenter prospective observational study to assess the impact of multivessel (MV) primary percutaneous coronary intervention (PCI) on clinical outcomes in 266 patients with ST-segment elevation myocardial infarction (STEMI) presenting with cardiogenic shock and resuscitated cardiac arrest.Patients with single vessel disease (SVD, 36.5%) had increased 6-month survival compared to those with multi-vessel disease (MVD, 29.6% vs. 42.3%, p = 0.032). Baseline characteristics were similar in those with MVD undergoing culprit-only (60.9%) or MV (39.1%) primary PCI. However, 6-month survival was significantly greater in patients who underwent MV PCI (43.9% vs. 20.4%, p = 0.0017). This survival advantage was mediated by a reduction in the composite of recurrent cardiac arrest and death due to shock (p = 0.024) in MV PCI patients. In those with MVD, culprit artery PCI success (hazard ratio 0.63; 95% CI 0.41 to 0.96, p = 0.030) and MV primary PCI (HR 0.57; 95% CI: 0.38 to 0.84, p = 0.005) were associated with increased 6-month survival.  Conclusion:  Multivessel primary PCI may improve  outcomes in patients with STEMI and multivessel disease presenting with cardiogenic shock and cardiac arrest.

Full Text:Mylotte. Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction, Resuscitated Cardiac Arrest, and Cardiogenic ShockThe Role of Primary Multivessel Revascularization. J Am Coll Cardiol Intv 2013;6(2):115-125

Editorial:  Kern. ST-Segment Elevation Myocardial Infarction, Cardiac Arrest, and Cardiogenic ShockAn Interventional Triumvirate of Opportunity. J Am Coll Cardiol Intv 2013;6(2):126-127

 

Editorial

Journal of Pharmacology & Pharmacotherapeutics:     Medical Education

 

Journal of Toxicology:     Medical Writing

 

Anesthesiology:     Haemoglobin

 

Commentary

British Medical Journal:     7 Day Working Week

 

Journal of the American Medical Association:     Tuberculosis

 

Canadian Medical Association Journal:     Microbiome

 

Review - Clinical

Neurological


HSR Proceedings in Intensive Care and Cardiovascular Anesthesia:     Subarachnoid Haemorrhage

 

Stroke Research and Treatment:     Stroke Therapy

 

Neurology Research International:     Cerebral Vasospasm

 

Transfusion:    Coagulopathy after Traumatic Brain Injury

 

Circulatory


HSR Proceedings in Intensive Care and Cardiovascular Anesthesia:     Sterno-Mediastinitis

 

HSR Proceedings in Intensive Care and Cardiovascular Anesthesia:     Cardiovascular Perfusion

 

HSR Proceedings in Intensive Care and Cardiovascular Anesthesia:     Coronary Artery Surgery

 

HSR Proceedings in Intensive Care and Cardiovascular Anesthesia:     Thoracic Aortic Surgery

 

Shock:     Nitric Oxide Donor Agents

 

Experimental and Therapeutic Medicine:     Cardiac Stem Cells

 

Transfusion:    Near Infrared Spectroscopy

 

Cardiology Research and Practice    

 

Respiratory


Anesthesiology:     Trauma-Induced Respiratory Failure

 

Wilderness & Environmental Medicine:     Surgical Cricothyroidotomy

 

Respiratory Care:     Modes of Ventilation

 

Gastrointestinal


 Journal of the American College of Surgery:     Abdominal Compartment Syndrome

 

World Journal of Gastroenterology:     Acute Pancreatitis

 

European Review for Medical and Pharmacological Sciences:     Intestinal Microbiota

 

Nutrition


Nutrients:     Perioperative Feeding

 

Nutrients:     Feeding the Malnourished Surgical Patient

 

Nutrients:     Nutrition in Burns

 

Nutrients:     Critical Care Nutrition

 

Hepatobiliary


Journal of the American College of Surgeons:     Neuroendocrine Liver Metastasis

 

Haematological


Transfusion:    Massive Transfusion

 

Transfusion:     Traumatic Coagulopathy

 

Anesthesiology:     Perioperative Plasmapheresis

 

Thrombosis:     New Oral Anti-Coagulants

 

Thrombosis:     New Oral Anti-Coagulants for Stroke Prevention

 

Thrombosis and Haemostasis:     Venothromboembolism Prophylaxis

 

Energency Medicine Journal:     Dabigatran

 

Sepsis


North American Journal of Medical Sciences:     New Antibacterials

Seminars in Immunopathology:     Staphlococcus Aureus

Fungal Biology Reviews:     Anti-Fungal Proteins

Trauma


Transfusion:     Haemorrhage Control

 

Transfusion:     Damage Control Resuscitation

 

Transfusion:    Microcirculation and Traumatic Coagulopathy

 

Transfusion:    Tranexamic Acid

 

Toxicology


Shock:     Alcohol Abuse

 

Journal of Natural Science, Biology and Medicine:     Bioterrorism

 

Immunology


Allergy:     Mast Cell

 

Allergy:     Churg-Strauss Syndrome

 

End-of-Life


Journal of Critical Care:     Do-Not-Resuscitate

 

Journal of Critical Care:     End-of-Life Decisions

 

Journal of Critical Care:     American Rare Donor Programme

 

Psychiatry


European Review for Medical and Pharmacological Sciences:     Psychiatric Emergencies

 

Miscellaneous


Anesthesiology:     Situational Awareness

 

Journal of Pharmacology & Pharmacotherapeutics:     Hedgehog Inhibitors

 

Clinical Cardiology:     Paediatric Cardiology

 

Review - Basic Science

Young Scientists Journal:     Stem Cells

 

Review - Non-Clinical

BMC Medicine:     Evidence-Based Medicine

 

 

I hope you find these brief summaries and links useful.


Until next week

Rob

 

{unsubscribe}If you would prefer not to receive these newsletters, please unsubscribe via this link{/unsubscribe}

 

 

 

 

Search